Stock listing

Agenus Inc.

Selected listing: A403RK · LSX · EUR · DE

Agenus Inc. (LS Exchange: A403RK), Health Technology. Latest release Oct 3, 2026: Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent…

A403RK:LSXEURDEUpdated October 2, 2026

Ticker: LS Exchange: A403RK
Asset type: Stock
Sector: Health Technology
Industry: Biotechnology
Exchange: LS Exchange
Currency: EUR

Latest news from Agenus Inc.

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

October 3, 2026

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

October 2, 2026

Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026

October 2, 2026

Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026

October 1, 2026

Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

September 10, 2026

All Agenus Inc. news →

Events

Replays

Agenus Inc. (AGEN) Q2 2025 Earnings Call
Wed, Aug 27, 2025 · 09:30 AM ET
Watch
Agenus Inc. (AGEN) Q4 2024 Earnings Call
Tue, Mar 11, 2025 · 08:30 AM ET
Watch
Agenus Inc. (AGEN) Q3 2024 Earnings Call
Tue, Nov 12, 2024 · 08:30 AM ET
Watch

Research Agenus Inc.

Agenus Inc. company profile

View the public company page for Agenus Inc. on 6ix.

Agenus Inc. news

Read company news and market updates connected to Agenus Inc..

Agenus Inc. investor events

Find investor webinars, events, and replay context for Agenus Inc..